Shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) have been given an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price objective of $10.00 for the company and are anticipating that the company will post ($0.17) earnings per share for the current quarter, according to Zacks. Zacks has also given Titan Pharmaceuticals an industry rank of 64 out of 256 based on the ratings given to its competitors.
Several brokerages have issued reports on TTNP. Maxim Group began coverage on shares of Titan Pharmaceuticals in a report on Wednesday, June 26th. They set a “buy” rating and a $4.00 target price on the stock. ValuEngine upgraded shares of Titan Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday.
An institutional investor recently raised its position in Titan Pharmaceuticals stock. Geode Capital Management LLC grew its position in Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) by 256.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 341,474 shares of the specialty pharmaceutical company’s stock after acquiring an additional 245,565 shares during the quarter. Geode Capital Management LLC owned about 2.63% of Titan Pharmaceuticals worth $76,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.06% of the company’s stock.
Shares of NASDAQ TTNP traded up $0.05 during mid-day trading on Friday, reaching $1.13. The company had a trading volume of 61,237 shares, compared to its average volume of 696,145. The stock’s 50-day moving average price is $1.28. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.86 and a current ratio of 2.12. The firm has a market cap of $15.13 million, a PE ratio of -1.43 and a beta of 1.00. Titan Pharmaceuticals has a 52 week low of $1.03 and a 52 week high of $5.64.
Titan Pharmaceuticals (NASDAQ:TTNP) last posted its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.08). Titan Pharmaceuticals had a negative return on equity of 311.18% and a negative net margin of 168.23%. The company had revenue of $0.95 million during the quarter. As a group, sell-side analysts predict that Titan Pharmaceuticals will post -0.68 earnings per share for the current year.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on treatments for chronic diseases. The company offers Probuphine, a product candidate for maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.
Featured Story: What does it mean to hold a stock in street name?
Get a free copy of the Zacks research report on Titan Pharmaceuticals (TTNP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.